Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia

With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk for SPMs among CLL survivors from the Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2019-09, Vol.9 (10), p.75-10, Article 75
Main Authors: Kumar, Vivek, Ailawadhi, Sikander, Bojanini, Leyla, Mehta, Aditya, Biswas, Suman, Sher, Taimur, Roy, Vivek, Vishnu, Prakash, Marin-Acevedo, Julian, Alegria, Victoria R., Paulus, Aneel, Aulakh, Sonikpreet, Iqbal, Madiha, Manochakian, Rami, Tan, Winston, Chanan-Khan, Asher, Ailawadhi, Meghna
Format: Article
Language:English
Subjects:
692/499
692/699/67/1990/283/1895
Adolescent
Adult
Aged
Aged, 80 and over
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer Survivors - statistics & numerical data
Chemotherapy
Female
Hematology
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology
Male
Middle Aged
Multivariate Analysis
Neoplasms, Second Primary - epidemiology
Oncology
Risk
SEER Program
Surveillance
United States - epidemiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk for SPMs among CLL survivors from the Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to risk of individual malignancies expected in the general population. In ~270,000 person-year follow-up, 6487 new SPMs were diagnosed with a standardized incidence ratio (SIR) of 1.2 (95% CI:1.17–1.23). The higher risk was for both solid (SIR 1.15; 95% CI:1.12–1.18) and hematological malignancies (SIR 1.61; 95% CI:1.5–1.73). The highest risk for SPMs was noted between 2 and 5 months after CLL diagnosis (SIR 1.57; 95% CI:1.41–1.74) and for CLL patients between 50- and 79-years-old. There was a significant increase in SPMs in years 2003–2015 (SIR 1.36; 95% CI:1.3–1.42) as compared to 1973–1982 (SIR 1.19; 95% CI:1.12–1.26). The risk of SPMs was higher in CLL patients who had received prior chemotherapy (SIR 1.38 95% CI:1.31–1.44) as compared to those untreated/treatment status unknown (SIR 1.16, 95% CI:1.13–1.19, p  
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-019-0237-1